BETHLEHEM, Pa., June 7, 2013 /PRNewswire/ -- Catheter-related bloodstream infections (CRBSIs), needlestick (sharps) injuries and exposure to potentially deadly blood borne pathogens continue to be major areas of concern for healthcare workers throughout the U.S.
"We are committed to addressing these issues by providing a robust portfolio of safety-engineered IV therapy devices that offer patient protection against infection and optimum safety in the workplace," said Tom Sutton, Vice President of Vascular Access Systems at B.Braun.
B. Braun Medical Inc. (B.Braun) will exhibit (booth #1316) its safety-engineered IV therapy devices at the 40th Annual Association for Professionals in Infection Control and Epidemiology (APIC) Conference, in Fort Lauderdale, Florida, June 8-10.
B.Braun 's portfolio includes safety-engineered IV therapy devices such as:
- Introcan Safety® IV Catheter, which is designed with innovative passive-safety features to help eliminate accidental needlestick injury - effortlessly. From insertion to catheter deployment to needle removal, clinicians are protected by a truly passive safety device that is activated automatically - no extra steps required and cannot be bypassed.
- Introcan Safety® 3 Closed IV Catheter, B.Braun's latest innovation, which takes the same preferred passive safety-engineered needlestick protection found in Introcan Safety and adds additional protection from blood exposure. For safety and convenience, the Introcan Safety 3's unique multi-access blood control septum minimizes blood exposure during needle removal and each time the catheter hub is accessed.
- The ULTRAPORT™ series of stopcocks, were designed in response to growing concerns about stopcock contamination. They feature disinfectable luer activated connectors that are more effective than conventional caps in preventing the passage of microorganisms in the catheter lumen. ULTRAPORT and ULTRAPORT zer0 luer-activated high-flow stopcocks, offer closed system protection against CRBSI and are designed to prevent contamination and leaks without caps. Research shows that infection control measures in the anesthesia work area may help reduce infections.1
- Caresite® Luer Access Device, the latest in B.Braun's needleless connector portfolio that offers a safe way to access IV lines without the use of a needle, which reduces the risk of accidental needlestick injuries. Input from clinicians provided the basis for the CARESITE design. The result is a device designed to help improve patient outcomes and clinician efficiency. CARESITE needleless connector with innovative positive displacement feature is designed to help reduce catheter occlusions while preventing healthcare workers from accidental needlestick injuries.
Attendees will be able to sign-up at B.Braun's booth (#1316) to receive reprints of studies that will inform them about the infections risks to healthcare workers from needlestick injuries and blood exposure with peripheral IV catheters and about the relative safety profiles of active vs. passive safety-engineered IV catheter designs. In addition, they will be able to order reprints that will inform them about the transmission of pathogenic bacterial organisms and the prevention of intravenous bacterial injection from healthcare provider hands.
To learn more about B.Braun visit www.bbraunusa.com
B. Braun Medical Inc. (B.Braun), a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the healthcare industry. The Company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. Guided by its "Sharing Expertise®" philosophy, B.Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs.
The B.Braun Group of Companies in the U.S. includes B.Braun, Aesculap® and CAPS®. B.Braun's U.S. headquarters is located in Bethlehem, Pennsylvania. The B.Braun Group of Companies employs more than 46,000 employees in more than 50 countries throughout the world. To learn more about B.Braun visit www.BBraunUSA.com.
1Loftus R, Koff MD, Burchman CC., et al. Transmission of pathogenic bacterial organisms in the anesthesia work area. Anesthesiology. 2008. 109:3 Related medicine technology :1
. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average2
. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-20123
. Watching, Reading and Listening: A New Way to Interact with Patient Information4
. Phreesia identifies over 26% of patients who require additional autism evaluation5
. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study6
. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan7
. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma8
. New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinsons disease9
. Patient Advocate Foundation Announces New Co-Pay Relief (CPR) Offerings for Patients Facing Health Issues Due to Electrolyte Imbalance10
. Quest Diagnostics Establishes Unique Healthcare Identifier to Improve Access to Vital Patient Health Information; 80 Million Patient IDs Created to Date11
. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way